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Background. Despite the high technical expertise in percutaneous mitral commissurotomy (PMC), mitral regurgitation (MR)
remains a major procedure-related complication. The aim of this work is to ﬁnd out the most sensitive and applicable predictors
of development of signiﬁcant mitral regurgitation (SMR) following percutaneous mitral commissurotomy using Inoue balloon
technique. Methods. We studied prospectively the preprocedural (clinical, echocardiography, and hemodynamic) and procedural
predictors of signiﬁcant mitral regurgitation (identiﬁed as increase of ≥2/4 grades of pre-PMC MR by color Doppler ﬂow
mapping) following valvuloplasty using Inoue balloon in 108 consecutive patients with severe mitral stenosis. Multiple stepwise
logistic regression analysis was performed for variables found positive on univariate analysis to determine the most important
predictor(s) of developing SMR. Results. The incidence of SMR following PMC using Inoue technique was 18.5% (10 patients).
MV scoring systems were the only variables that showed signiﬁcant diﬀerences between both groups (Group A without SMR and
Group B with SMR). However, no clinical, other echocardiographic measurements, hemodynamic or procedural variables could
predict thedevelopment of SMR.Usingmultipleregression analysis,thebestpredictive factor for theriskofSMR after InoueBMV
was the total MR-echo score with a cutoﬀ point of 7 and a predictive percentage of 97.7%. Conclusions. The total MR-echo score is
the only independent predictor of SMR following PMC using Inoue technique with a cutoﬀ point of 7.
1.Introduction
Rheumaticfeveristhemostcommoncauseofacquiredheart
diseases in children, young, and middle-aged adults world-
wide. The disease is endemic in developing countries includ-
ing Middle East countries [1]. Mitral stenosis (MS) is almost
invariably the result of chronic rheumatic heart disease sec-
ondary to one or more prior episodes of acute rheumatic
fever [1]. Since Inoue et al. introduced balloon valvuloplasty
in 1984, this procedure has become the treatment of choice
replacing surgical commissurotomy in many cases [2].
Despite the high technical expertise in percutaneous mitral
commissurotomy (PMC), mitral regurgitation (MR) re-
mains a major procedure-related complication [3]. The in-
cidence of severe MR after PMC in the literature varies
between 1.4% and 7.5% [4–6]. Many studies using diﬀerent
techniques of PMC have identiﬁed mitral valve anatomy as
a predictive factor of the immediate results. However, the
global echocardiographic classiﬁcations have some limita-
tions [7]. This study aimed at ﬁnding out the most sensitive
and applicable predictors of the development of signiﬁcant
mitral regurgitation (SMR) following PMC using Inoue
balloon technique whether preprocedural or procedural.
2. Methods
We prospectively included 108 consecutive patients with
rheumatic mitral stenosis who are subjected to PMC using
Inoue balloon technique during the period from February
2007 to October 2009 in two centers in the Middle East,
Tanta University Hospital in Egypt and King Fahad Medical
City in Saudi Arabia. Our study is conformed to the Helsinki
Declaration. The Institutional Review Board (IRB) approved2 Cardiology Research and Practice
the study in both centers. All patients gave informed consent
to participate in the study.
Inclusion criteria included symptomatic MS with NYHA
f u n c t i o n a lc l a s sI Io rm o r ew i t hm i t r a lv a l v ea r e a( M V A )
≤1.5cm2 and mitral valve Echocardiographic score ≤11
according to scoring system described by Wilkins et al. [8].
Exclusion criteria were patients with MR or aortic regurgita-
tion (AR) of grade II/IV or more, also, patients with Wilkins
scoring of >11 [8] and presence of left atrial (LA) thrombi
assessed by transesophageal echocardiography (TEE). To
avoid personal bias in assessing the anatomic scores and the
mitral valves, these parameters were graded by at least two
readers and in case of disparity by a third one to ensure
correct classiﬁcation.
Patients were divided into two groups according to the
developmentofSMRornot:GroupA(patientswithoutSMR)
and Group B (patients who developed SMR). All patients
were subjected to full history taking and clinical examina-
tion, standard resting 12-lead electrocardiogram.
Transthoracic echocardiographic and Doppler examina-
tions were done within a week before intervention and one
day after the procedure. Examination was acquired with the
patients in the left lateral decubitus position by using a com-
mercially available system (Vingmed Vivid Seven, General
Electric—Vingmed, Milwaukee, WI, USA) equipped with
2.5 and 3.5MHz transducers and 5MHz transesophageal
monoplane transducer.
We studied mitral valve morphology using diﬀerent
scoring systems including Massachusetts General Hospital
score by Wilkins et al. [8], MR-echo score by Padial et al. [9],
and Commissural score by Sutaria et al. [10]. We also meas-
ured mitral valve area (MVA), LA dimensions, transmitral
maximum pressure gradient (MG), estimated systolic pul-
monary artery pressure (SPAP), and presence of MR and its
severity. Severity of MR was determined by expressing the
ratio of maximal jet area to left atrial area in the same view
using color ﬂow mapping and graded from one to four
according to Essop et al. [11]. SMR was deﬁned as the
increase of ≥2/4 grades of MR. Furthermore, other quantita-
tive measures such as vena contracta or PISA methods were
usedtoassesstheseverityofMRincasesofuncertaintyabout
the use of maximal regurgitant jet area.
Transesophageal echocardiography (TEE) was done one
day preintervention for exclusion of LA and LA appendage
thrombi, measuring of interatrial septal thickening, and
reassessment of transthoracic echocardiographic data.
Invasive hemodynamic study included predilatation and
early postdilatation assessment of LA pressure, left ventricu-
lar end-diastolic (LVED) pressure, and transmitral pressure
gradient (PG).
PMCusingInouetechniquewasdoneasdescribedbefore
in the literature [12].
3.StatisticalAnalysis
Data are presented as mean ± SD. Categorial variables were
compared using Student’s t-test. Nonparametric data were
compared using Chi-square test. Multiple stepwise logistic
regression analysis was performed for variables found pos-
itive on univariate analysis to determine the most important
predictor(s) of developing SMR. P value was considered
signiﬁcantwhenitwas<0.05.DatawerecollectedusingSPSS
version 16.
4. Results
This study prospectively included consecutive 108 patients
with mitral stenosis who were subjected to PMC using Inoue
technique. Using Doppler color ﬂow imaging before the
procedure, 94 patients (87%) had no MR and 14 patients
had (13%) grade +1MR. After the procedure, 36 patients
(33.3%) still had no MR and 52 patients (48.2%) had grade
+1MR. However, 2 patient (1.8%) developed grade +2MR,
8 patients (7.4%) grade +3MR, and 10 patients (9.3%)
grade +4MR. So, the incidence of postprocedure SMR and
severe MR in our study was 18.5% and 9.3%, respectively.
According to the development of SMR, we divided our
patients into two groups (Group A, 88 patients without SMR
and Group B, and 20 patients with SMR). There were no
signiﬁcant diﬀerences between both groups regarding their
baseline clinical characteristics, echocardiographic measure-
ments other than MV scoring, preprocedural hemodynamic,
and procedural data (Tables 1 and 2).
MV Morphology and Scoring Systems (Table 3):
(a) Wilkins Score: the calciﬁcation score and the total
score were signiﬁcantly higher in group B than in
Group A (P = 0.006, 0.028, resp.);
(b) MR-echo Score: the total score and all of its com-
ponents except subvalvular disease were signiﬁcantly
higher in Group B (P = 0.001);
(c) Commissural Score: it was also signiﬁcantly higher in
group B (P = 0.003).
4.1. Predictors of SMR. As the MV scoring systems were the
only variables that showed signiﬁcant diﬀerences between
both groups, and using multiple regression analysis, we
found that the best predictive factor for the risk of SMR after
Inoue BMV is the total MR-echo score with a cutoﬀ point of
7 and a predictive percentage of 97.7%.
5. Discussion
The large number of patients with mitral stenosis (MS)
may require some modality of invasive treatment during
their life [13]. The therapeutic approach to MS has evolved
considerablysince1984,aftertheﬁrstreportofpercutaneous
balloon mitral valvuloplasty by Inoue et al. [2]. Since that
time, percutaneous balloon mitral valvuloplasty has become
a common treatment of mitral stenosis [2]. Severe MR after
PMC remains one of the most important complications of
this procedure [6]. Risk of SMR is deﬁned as an increase of
≥2/4 grade of MR [11]. However, the precise factors predict-
ing SMR are not fully understood and rather controversial
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Table 1: Baseline Characteristics.
Variable Group A
(n = 88)
Group B
(n = 20) P value
Clinical Characteristics:
(i) Age (Years) 31 ±93 2 ±10 0.86
(ii) Male/Females 22/66 6/14 0.58
(iii) Height 159 ±7 157 ±50 . 8 1
(iv) BSA 1.6 ±0.21 .6 ±0.30 . 9 2
(v) Prior PMC 13.6% 15.8% 0.95
(vi) NYHA Class 2.6 ±0.72 .7 ±0.80 . 9 4
(vii) AF 27.2% 31.6% 0.59
Pre-PMC Echo-Doppler data (except MV Scoring):
(i) MVA (cm2)0 .9 ±0.20 .8 ±0.20 . 3 7
(ii) MG 14 ±31 3 ±20 . 7 1
(iii) SPAP 44 ±20 41 ±21 0.67
(iv) LA dimension 4.8 ±1.04 .9 ±0.70 . 4 7
BSA: body surface area; NYHA: New York Heart Association classiﬁcation;
AF: atrial ﬁbrillation. ∗Signiﬁcant at <0.05
Table 2: Hemodynamic and procedural data.
Variable Group A
(n = 88)
Group B
(n = 20) P value
Pre-Procedural Hemodynamic Data:
(i) LAP 25.8±6.63 0 .3±5.70 . 1 6
(ii) LVEDP 6.3 ±2.05 .9 ±2.40 . 5 7
(iii) Transmitral PG 20.5±6.82 4 .3±8.10 . 1 4
Procedural (Technical) Data:
(i) Balloon Size 26.5±0.92 6 .0±1.10 . 2 7
(ii) No. of Inﬂations 2.0 ±0.92 .1 ±1.10 . 2 8
∗Signiﬁcant at <0.05
The present study prospectively included 108 patients
with rheumatic mitral stenosis who were subjected to PMC
using Inoue balloon technique. They were divided according
to the development of SMR into two groups, Group A (88
patients without SMR) and Group B (20 patients with SMR).
Inourstudy, theincidence ofSMRwas18.5% andthat of
severe MR was 9.3% following PMC with Inoue technique.
Echo-Doppler clariﬁed the mechanisms of development of
SMR as follow: a tear of the posterior mitral leaﬂet in 10
patients, a tear of the anterior leaﬂet in 8 patients, and 1
patient had chordal rupture. The incidence of severe MR
after balloon mitral valvotomy in the literature varies be-
tween 1.4% and 7.5% [4–6]. Zaki et al. reported postpro-
cedural severe MR in 9.8% of patients with MS undergone
balloon mitral valvuloplasty (BMV) [14]. Similarly, Kasem
et al. reported that the incidence of severe MR after PMC
using Inoue balloon technique was 10% [15]. Hernandez et
al. reported that 31% of their patients had an increase in MR
grade but only 6.6% developed severe MR [4]. Also, Mezillis
et al. reported severe MR in 9% of their patients [16]. So, our
results regarding the incidence of severe MR are comparable
to most of previously done studies. Regarding the incidence
of SMR and in agreement with our results (18.5%), that of
Table 3: MV Scoring Systems.
Variable Group A
(n = 88)
Group B
(n = 20) P value
(A) Wilkins Score:
(i) Mobility 2.4 ±0.52 .7 ±0.90 . 3 8
(ii) Thickening 2.2 ±0.42 .3 ±0.50 . 5 9
(iii) Subvalvular 1.5 ±0.51 .7 ±0.70 . 4 8
(iv) Calciﬁcation 0.9 ±0.72 .0 ±0.7 0.006∗
(v) Total Score 7.1 ±1.78 .9 ±2.1 0.028∗
(B) MR-echo Score:
(i) Anterior Leaﬂet 1.8 ±0.72 .5 ±0.5 0.024∗
(ii) Posterior Leaﬂet 1.6 ±0.62 .5 ±0.7 0.010∗
(iii) Commissures 1.2 ±0.52 .5 ±1.1 0.002∗
(iv) Subvalvular 1.5 ±0.51 .7 ±0.70 . 4 9
(v) Total Score 6.2 ±1.09 .3 ±1.4 0.001∗
(C) Commissural Score:
(i) Total Score 0.7 ±0.62 .0 ±0.9 0.003∗
∗Signiﬁcant at <0.05
Essop et al. was 17.5% and Mezillis et al. was 17% of their
patients [11, 16].
There were no signiﬁcant diﬀerences between both
groups regarding baseline clinical data, echocardiographic
measurements other than MV scoring, preprocedural hemo-
dynamic data, or procedural (technical) data. These results
came in agreement with several previous studies where no
clinical, echocardiographic (with exception of MV Scoring),
procedural, or hemodynamic predictors forthe development
o fS M Ro rs e v e r eM Rf o l l o w i n gI n o u eB M Vw e r ef o u n d
[4,5,11,17–19].Incontradictorytotheresultsofthepresent
study, smaller MVA, higher MG and LA dimension were
proposed by Mailer et al. to be predictors for the devel-
opment of MR following Inoue BMV [20]. Also, Cho et al.
reported the initial MVA as a determinant of increase MR
following Inoue technique [21].
Regarding Wilkins score, both the calciﬁcation score
and total score were signiﬁcantly higher in group B (those
developed SMR). For MR-echo score, all the anterior leaﬂet,
posterior leaﬂet, and total scores were higher in group B.
Also, the commissural score was signiﬁcantly higher in
group B. So, using backward elimination logistic regression
analysis, we applied three predictive models for SMR after
PMC with Inoue technique. From these three models, the
best predictive factor for the risk of SMR was the total MR-
echo score. In agreement with our results, several previous
trials failed to predict SMR following PMC with Inoue
technique using total Wilkins score [11, 19, 22–25].
However,incontradictorytoourresults,Chenetal.iden-
tiﬁed the severity of subvalvular disease as an independent
predictor of increase MR severity after BMV [26]. Garc´ ıa-
Castillo et al. identiﬁed total Wilkins score >8 as an inde-
pendent predictor of severe MR which is also against our
results [27]. However, both Garc´ ıa-Castillo et al. [27]a n d
Inoue et al. [28] have some agreement with our results where
commissural calciﬁcation was a predictor of developing4 Cardiology Research and Practice
SMR. Regarding commissural score, the results of Sutaria
et al. [10] came in agreement with our results that failed to
use it as a predictor of development of SMR following BMV
with Inoue technique.
Regarding MR-echo score, Padial et al. identiﬁed it as
the only independent predictor for developing severe MR
after Inoue technique using a total score of >10 as a cutoﬀ
point [9]. Also, Mezilis et al. reported that MR-echo score
is better at reliably identifying patients at risk of developing
SMRaftertheInouetechniquewithsensitivityandspeciﬁcity
of 83% and 100%, respectively, using 8 as a cutoﬀ point [16].
These results came in agreement with our study, although
the cutoﬀ point in our study was 7. Limitations: we tested
SMR following PMC using only Inoue technique but not
other techniques such as multitrack balloon technique. Also,
we did not evaluate other new MV scoring systems such
as Cormier’s grading of mitral valve anatomy [29] and that
developed by Rifaie et al. [30].
6. Conclusions
We concluded from our study that no baseline clinical
characteristics, preprocedural hemodynamic data, or proce-
dural techniques were predictors of SMR following Inoue
BMV. Regarding echocardiographic predictors of SMR, the
total MR-echo score developed by Padial et al. is the only
independent predictor of SMR following PMC using Inoue
technique with a cutoﬀ point of 7.
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